Ahmedabad: Homegrown pharma major, Torrent Pharmaceuticals Limited, posted a 52% growth in its profit after tax (PAT) at Rs 443 crore in the third quarter of FY 2024, from Rs 292 crore for the corresponding quarter last year.
The growth was driven by four launches in 2022 and three launches in 2023 as well as performance of top brands and growth in generic business, the company said in its stock exchange filing.
The company’s board approved an interim dividend of Rs 22 per equity share. TNN
We also published the following articles recently
The growth was driven by four launches in 2022 and three launches in 2023 as well as performance of top brands and growth in generic business, the company said in its stock exchange filing.
The company’s board approved an interim dividend of Rs 22 per equity share. TNN
We also published the following articles recently
Torrent Pharma Q3 profit after tax jumps 52%
Torrent Pharmaceuticals Limited reported a 52% growth in consolidated net profit for Q3 FY 2024, reaching Rs 443 crore. The company attributed the growth to launches in 2022 and 2023, top brands’ performance, and generic business growth. The board also approved an interim dividend of Rs 22 per equity share.
Torrent Pharmaceuticals Limited reported a 52% growth in consolidated net profit for Q3 FY 2024, reaching Rs 443 crore. The company attributed the growth to launches in 2022 and 2023, top brands’ performance, and generic business growth. The board also approved an interim dividend of Rs 22 per equity share.